Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$25 Mln
P/E Ratio
--
P/B Ratio
2.16
Industry P/E
28.11
Debt to Equity
0
ROE
-2.33 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.47
CFO
$-188.50 Mln
EBITDA
$-276.51 Mln
Net Profit
$-286.27 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
CEL-SCI Corp (CVM)
| -27.48 | 21.49 | -33.33 | -79.86 | -52.76 | -54.55 | -35.90 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
CEL-SCI Corp (CVM)
| -85.07 | 15.74 | -66.90 | -39.11 | 27.43 | 218.82 | 51.52 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.42 | 6,904.81 | -- | 38.11 | |
| 73.23 | 7,574.08 | 58.3 | 23.56 | |
| 60.43 | 11,448.88 | 394.4 | 0.76 | |
| 8.34 | 9,704.70 | -- | -3.24 |
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has... completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. Address: 8229 Boone Boulevard, Vienna, VA, United States, 22182 Read more
Chief Executive & Financial Officer, Treasurer and Director
Mr. Geert R. Kersten Esq.
Chief Scientific Officer
Dr. Eyal Talor Ph.D.
Headquarters
Vienna, VA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of CEL-SCI Corp (CVM) stood at $ 31 Mln as on 31-Dec-24
The share price of CEL-SCI Corp (CVM) is $0.29 (NYSE) as of 29-Apr-2025 16:10 EDT. CEL-SCI Corp (CVM) has given a return of -52.76% in the last 3 years.
CEL-SCI Corp (CVM) has a market capitalisation of $ 25 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of CEL-SCI Corp (CVM) is 2.16 times as on 28-Apr-2025, a 57% discount to its peers’ median range of 5.04 times.
Since, TTM earnings of CEL-SCI Corp (CVM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the CEL-SCI Corp (CVM) and enter the required number of quantities and click on buy to purchase the shares of CEL-SCI Corp (CVM).
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. Address: 8229 Boone Boulevard, Vienna, VA, United States, 22182
The CEO & director of Mr. Geert R. Kersten Esq.. is CEL-SCI Corp (CVM), and CFO & Sr. VP is Dr. Eyal Talor Ph.D..
There is no promoter pledging in CEL-SCI Corp (CVM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| CEL-SCI Corp (CVM) | Ratios |
|---|---|
|
Return on equity(%)
|
-275.85
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of CEL-SCI Corp (CVM) was $0 Mln.
$-0.01
(
